Erythromycin
Erythromycin has been studied in 5 papers since 2016: 2 observational studies in people, 1 in animals, 1 in cells, 1 review; 1 in the past year. The newest paper, Feb 11, 2026: “Association between urinary antibiotic exposure and blood pressure parameters in reproductive-age men: a biomonitoring-based cross-sectional study in China”.
See all 9 papers on erythromycin
At a glance
The findings reach worms or flies, none yet in people. 2 independent labs in 2 countries; 11 trials, none about aging, 7 with no results posted.
None of its findings points the other way.
- 2 independent labs in 2 countries
- 11 trials, none about aging, 7 with no results posted
- Funders: Georgia Institute of Technology and 4 more
- Humans2
- Model organisms1
- Cells1
What did studies of erythromycin find?
2Studies of erythromycin measured 2 outcomes: cellular senescence and lifespan.
Cellular senescence
no changein human cells1
1 study
Cellular senescence
no changein human cells1
Erythromycin showed no clear effect on cellular senescence in human cells after BrdU-induced senescence.
“Erythromycin - the very closely-related parent compound - did not show any senolytic activity”
Cellsafter BrdU-induced senescence
Aging
Lifespan
upin Rotifera1
1 study
Lifespan
upin Rotifera1
Erythromycin extends lifespan in Rotifera.
“Exposures to 1 μM erythromycin, 5 μM carglumic acid, 3 μM capecitabine, and 1 μM ivermectin, extended rotifer lifespan without significant effect on reproduction.”
Model organisms1 μM
Biogerontology
Who is developing erythromycin?
1 company: AstraZeneca.
- Companies
- AstraZenecaPhase 1
Trial sponsors
Company1 trialPhase 3201 people
Company1 trialPhase 3139 people
Company1 trialPhase 2/397 people
Shanghai Fosun Pharmaceutical Industrial Development
Company1 trialPhase 247 people
Company1 trialPhase 1/2952 people
Janssen Research & Development
Company2 trialsPhase 155 people
Company1 trialPhase 1172 people
Company1 trialPhase 149 people